Identifying biomarkers for a new ovarian cancer therapy
Official title: Developing biomarkers of response for a new therapy in ovarian cancer
Funded at University of Pennsylvania · NIH-11036275 · Data updated 2026-11-12
This study is looking at clear cell ovarian cancer and aims to find ways to predict which patients will respond best to a new treatment that targets specific genetic changes, so that doctors can personalize care and improve outcomes for those affected.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | February 15, 2024 |
| Project end | December 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $609,174 |
| NIH project number | 5R01CA285965-02 |
| Project ID | NIH-11036275 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with clear cell ovarian cancer, particularly those with ARID1A mutations.
✕Less likely to help
Patients with other subtypes of ovarian cancer or those without ARID1A mutations may not benefit from this research.
What this research studies
This research focuses on clear cell ovarian cancer (CCOC), a subtype that is difficult to treat due to its resistance to standard chemotherapy. The study aims to develop biomarkers that can predict how well patients will respond to a new combination therapy targeting specific genetic mutations. By analyzing human samples and using patient-derived tumor models, the researchers will identify which patients are most likely to benefit from this innovative treatment approach. The ultimate goal is to improve patient outcomes by personalizing therapy based on these biomarkers.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with clear cell ovarian cancer.
How similar studies have gone: Previous research has shown promise in using biomarkers to tailor cancer therapies, indicating that this approach could be effective.
Where this research is happening
-
University of Pennsylvania
Philadelphia, United States Active
Researchers
- Principal investigator: Simpkins, Fiona — University of Pennsylvania
- Study coordinator: Simpkins, Fiona
Related research
Other NIH-funded projects on the same topics.
-
Understanding the experience of ovarian cancer after diagnosis to improve survivorship
This NIH grant funds a mixed-methods study to better understand physical and emotional challenges faced by ovarian cancer survivors and how supportive care can help them live better after diagnosis.
-
Targeting quiescent ovarian cancer cells to overcome chemotherapy resistance
A study focusing on why some ovarian cancer cells pause dividing and resist chemotherapy, with the goal of finding new treatment targets for relapsed disease.
-
Photodynamic lipids to boost chemotherapy for metastatic ovarian cancer
A patient-friendly approach tests a light-activated method to make ovarian cancer metastases more sensitive to chemotherapy.
-
Integrated framework to validate and quantify proteoforms in patient-derived ovarian cancer cells
A collaboration will combine advanced top-down proteomics with a new computational method to precisely identify and measure intact proteoforms in tiny samples from ovarian cancer cells.
-
Overcoming platinum resistance in ovarian cancer: finding biomarkers and new targets
Researchers are looking for new biomarkers and targets to help prevent or overcome platinum resistance in high‑risk ovarian cancer so patients have better chances at long-term control.
-
Alternative NF-kB activation after chemotherapy in ovarian cancer
This grant studies how ovarian cancer might come back after chemotherapy by looking at specific signaling pathways in cancer cells and the tumor environment.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.